natgillin/translations-raw huggingface dataset:
A method for molding interior and exterior members of vehicles by using a mold having a cavity plate, the method comprising the steps of: 
Postupak oblikovanja unutarnjih i vanjskih dijelova (4) uz upotrebu kalupa koji ima udubljenu ploču, naznačen time što se postupak sastoji u koracima:
The apparatus of claim 1, wherein the vessel is removably coupled to the valve. The apparatus of claim 1, wherein the gas chromatograph is coupled to the inlet and the apparatus provides a non-composite sample of the fluid flowing through the conduit to the gas chromatograph. 
Uređaj prema bilo kojem od gornjih zahtjeva, naznačen time da je plinski kromatograf (114) spojen na ulaz (104) i regulator je nadalje konfiguriran da osigurava ne-kompozitni uzorak fluida koji struji kroz vod (106) do plinskog kromatografa (114).
reduction of compound 2, particularly with diisobutylaluminium hydride to create compound D; 
redukcija spoja 2 ili spoja 2*, osobito s diizobutilaluminij hidridom kako bi se dobio spoj D odnosno D*;
to 250 g per liter PEG having an average molecular weight of 2500 to 4500 Da; 
(1) 52,5 do 187,5 g po litri PEG prosječne molekulske težine od 2500 do 4500 Da;
reaction of a compound of formula (IX) with a compound of formula (XV): 
u kojem je RI jest ravni ili razgranati C,-Cg alkil ili Cz-Cg-cikloalkil, pri čemu nastaje spoj formule (X):
R1-R2 are independently selected from hydrogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, and C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl or R1 and R2 together with the nitrogen form a 4-7 membered ring containing zero or one double bond, optionally said ring in addition to said nitrogen comprises one further heteroatom selected from nitrogen, oxygen and sulphur; 
- R-R? se nezavisno biraju iz vodika, C,.4-alk(en/in)il, C;_.g-cikloalk(en)il i C3 g-cikloalk(en), ili R!iR? zajedno s dušikom tvore 4-7-člani prsten koji sadrži nula ili jednu dvostruku svezu a, opcionalno, rečeni prsten, uz rečeni
The peptide of claim 2 or 3, wherein the C-terminal amino acid of the amino acid sequence of SEQ ID NO:376 or 379 is substituted with valine or leucine. 
Peptid u skladu s patentnim zahtjevom 2 ili 3, naznačen time što je C-terminalna aminokiselina u aminokiselinskom slijedu SEQ ID NO: 194, 174, 178 ili 186 zamijenjena fenilalaninom, leucinom, izoleucinom, triptofanom ili metioninom.
The first agent and the second agent for the use of claim 1, wherein said treatment or prevention comprises administering a further therapeutic agent and/or radiation therapy, wherein the further therapeutic agent is preferably an anti-neoplastic agent or an anti-tumor antibody or a chemotherapeutic agent, wherein the chemotherapeutic agent is preferably selected from the group consisting of capecitabine, anthracycline, doxorubicin, cyclophosphamide, paclitaxel, docetaxel, cisplatin, gemcitabine, and carboplatin. 
Prvo sredstvo i drugo sredstvo za upotrebu prema patentnom zahtjevu 1, naznačeno time što navedeno liječenje ili prevencija sadrži primjenu dodatnog terapijskog sredstva i/ili zračenja, gdje je dodatno terapijsko sredstvo poželjno antineoplastično sredstvo ili antitumorsko antitijelo ili kemoterapijsko sredstvo, gdje je kemoterapijsko sredstvo poželjno izabrano iz grupe koja se sastoji od kapecitabina, antraciklina, doksorubicina, ciklofosfamida, paklitaksela, docetaksela, cisplatina, gemcitabina i karboplatina.
The scooter according to claim 13, wherein the foot rest includes an extension on the rear frame part, a portion of the front frame part being positioned below the extension of the rear frame part in the collapsed position of the front and rear frame parts. 
Skuter prema jednom od prethodnih zahtjeva, gdje stražnji dio okvira (2) obuhvaća ručku (26) iza sjedala (24), pokretni član koji pokreće zaključavanje osi zakretanja i nalazi sc ispod ručke.
The process according to claim 9, wherein, during step d), the reaction of the a-halo acid with sodium hydroxide is optimal for a temperature in the region of 50° C. if the a-halo acid contains at least four carbons and for a temperature in the region of 90° C. if the a-halo acid contains less than four carbons. 
Postupak prema zahtjevu 9, naznačen time da je tijekom koraka d) reakcija a-halogenizirane kiseline s natrijevim karbonatom optimalna za temperaturu blizu 50*C ako a-halogenizirina kiselina ima najmanje četiri atoma ugljika, a za temperaturu blizu 90*C ako a-halogenizirana kiselina ima manje od četiri atoma ugljika.
or 2 copies of the minor allele, G, of rs916758, and or 2 copies of the minor allele, T, of rs1261134, wherein the presence of said biomarker indicates an increased risk for said adverse neurological event; and selecting a first method of treatment or a second method of treatment, wherein said first method of treatment and second method of treatment are dependent on whether said patient is likely to develop peripheral neuropathy in response to said treatment for cancer. 
1 ili 2 kopije rjeđeg alela, G, od rs916758, i 1 ili 2 kopije rjeđeg alela, T, od rs1261134, pri čemu prisutnost navedenog biomarkera ukazuje na povećani rizik za nastanak spomenutog štetnog neurološkog događaja; i odabir prvog postupka liječenja ili odabir drugog postupka liječenja, pri čemu su navedeni prvi postupak liječenja i drugi postupak liječenja ovisni o tome da li je vjerojatno da će navedeni pacijent razviti perifernu neuropatiju kao odgovor na navedeni tretman raka.
The invention relates to a crystalline form of 1-chloro-4-(B-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments. 
1-kloro-4<(B-D-glukopiranoza-1-il)-2-[4((S)-tetrahidrofuran-3-iloksi)-benzil]-benzen, naznačen time, da je barem 50% navedene supstancije prisutno u obliku kristaliničnog oblika u skladu sa zahtjevom 1 ili 2.
In an exemplary embodiment of the invention, the sticks have a hollow cross section. 
Vibrirajući uređaj za branje malog voća prema zahtjevu 1, pri čemu navedeni štapovi imaju šuplji poprečni presjek.
Embodiments of the present invention include those compounds wherein R2 is selected from the group consisting of hydrogen and C1-4alkyl. 
Spoj prema zahtjevu 1 naznačen time da R* je supstituent izabran iz skupine koju čine vodik i Cualkil.
The compound of claim 1, characterized by formula VI: 
Spoj predstavljen strukturom prema formuli VI:
A compound represented by the formula (I) wherein 
HR P20180483 T1 1. < Spoj, naznačen time, da je predstavljen formulom (I): gdje
The modified IgG4 Fc fragment of claim 1, wherein the hinge region was mutated by the deletion of 1 to 5 continuous or discontinuous amino acid(s) comprising a Cys residue at the 8th position. 
Modificirani IgG4 Fc fragment prema zahtjevu 1, naznačeno time da je zglobna Tegija mutirana putem brisanja od 1 do 5 uzastopne/ih ili neuzastopne/ih aminokiselina sadržeći C1s ostatak na osmom položaju.
Particularly suitable are monoesters of dicarboxylic acids such as monomethylglutarate and monomethyladipate. 
Osobito su prikladni monoesteri dikarboksilnih kiselina kao što je monometilglutarat i monometiladipat.
The cannabis extract of any of claims 5-7, wherein the first or second most abundant terpene in the terpene profile is selected from the group consisting of terpinolene, alpha pinene, limonene, and beta caryophyllene. 
Ekstrakt kanabisa u skladu s bilo kojim od patentnih zahtjeva 5-7, naznačena time što se prvi ili drugi najobilatiji terpen u terpenskom profilu bira iz skupine koju čine terpinolen, a-pinen, limonen, te B-kariofilen.
The external columns were packed with Fibra-Cel® disks (New Brunswick Scientific) according to the mass of carriers given in Table 1. 
Vanjska kolona sadrži punjenje diskova Fibra-Cel" (New Brunswick Scientific) sukladno masi nosača koja je dana u Tablici 1.
Such modifications are intended to fall within the scope of the appended claims. An anti-CD20 antibody formulation comprising a therapeutically effective amount of an anti-CD20 antibody, 10 to 100 mM sodium acetate, 25 to 100 mM sodium chloride, 0.5 to 5% arginine free base, 0.02 to 0.2 mM EDTA, 0.01 to 0.2 % polysorbate 80 and adjusted to pH 5.0 to 7.0, for use in the treatment of an immune disease and/or autoimmune disease. 
Formulacija protutijela anu-CID20, naznačena time, da obuhvaća od 20 do 300 mg/mL, ofatumumaba, od 10 do 100 miM natrijevog acetata, od 25 do 100 mM natrijevog klorida, od 0,5 do 5% slobodne baze arginina, od 0,02 do 0.2 mM EDTA, od 0,01 do 0,2% polisorbata 80, i podešava se na pH-vrijednost od 5,8 do 7,0, pri čem se ona upotrebljava u liječenju imunološke bolesti i/ili autoimune bolesti.
A pharmaceutical composition according to claim 5, wherein the molar ratio of meglumine to said HDAC inhibitor is at least 0.5 to 5. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 6, naznačen time, da je molarni odnos arginina prema spomenutom HDAC inhibiloru najmanje 0,5 do 5.
The method according to claim 21, wherein pozzolans, latent hydraulic materials, or combinations thereof are ground together with the ternesite clinker and/or the Portland cement clinker. 
Postupak sukladno zahtjevu 9, naznačen time što puzolani, latentni hidraulički materijali ili njihove kombinacije samljeveni su s ternesit klinkeromi/ili portland cement klinkerom.
A compound of formula (II), a salt, or a stereoisomer thereof. wherein 
Spoj formule (II), sol, ili a njegov stereoizomer R? R5 o
Method of Aspects of the Invention. 
Datum objave europskog patenta:
the local server (LS) records the time (T), the GSM number (N) and a change in position within the hierarchically ordered server content for the mobile device having the GSM number (N); and 
D. lokalni poslužitelj (LS) bilježi vrijeme (T), GSM broj (N) i promjenu u poziciji unutar hijerarhijski uređenog sadržaja na poslužitelju za mobilni uređaj s GSM brojem (N); i
Additionally, before the base unit 3 is connected to a container it comprises a seal (not shown) fixed to the upper edge of the outer wall 16. 
K tome, prije spajanja osnovne jedinice 3 na spremnik, ona ima brtvu (koja nije prikazana) učvršćenu za gornji rub vanjske stijenke 16.
or a pro-drug, stereoisomer, pharmaceutically acceptable salt or hydrate thereof, wherein, is halogen or C1-C6 alkyl; 
E oo ili stereoizomer, farmaceutski prihvatljiva sol ili hidrat istog, pri čemu R' je halogen ili CI-C6 alkil;
A sheet as claimed in claim 1, wherein the proportion of sheet material which is subjected to plastic strain of 0.05 or more is at least 65%. 
Lim (10) prema bilo kojem prethodnom zahtjevu, naznačena time da udio materijala za lim koji je podvrgnut plastičnoj deformaciji od 0.05 ili više je najmanje 65%.
A coating composition for the preservation of fresh produce comprising an aqueous emulsion of from 0.25 to 25% by weight of polyvinylidene copolymer, and 0.0005 to 10% surfactant. 
Oblagajuća kompozicija za održavanje proizvoda svježim, naznačena time, što sadrži vodenu emulziju od 0.25 do 25 masenih % poliviniliden kopolimera, i 0.0005 do 10% površinski aktivnog sredstva.
represents a hydrogen atom; and R4 represents a phenyl group which may have 1 to 2 substituents selected from a halogen atom, a cyano group, a nitro group, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a halogenoalkoxy group having 1 to 6 carbon atoms, a cycloalkyl-alkoxy group having 3 to 7 carbon atoms, a cycloalkoxy group having 3 to 7 carbon atoms, a carboxyl group, an alkoxycarbonyl group having 1 to 6 carbon atoms, and an acyloxy group, a naphthyl group which may have a mono- or dialkylamino group as a substituent, or a thienyl group which may have a halogen atom as a substituent. 
R* predstavlja atom vodika; i R* predstavlja skupinu fenila koja može imati 1 do 2 supstituenta odabrana od atoma halogena, cijano skupine, nitro skupine, skupine alkila koji ima 1 do 6 ugljikovih atoma, skupine alkenila koja ima 2 do 6 ugljikovih atoma, alkoksi skupine koja ima 1 do 6 ugljikovih atoma, halogenoalkoksi skupine koja ima 1 do 6 ugljikovih atoma, cikloalkilalkoksi skupine koja ima 3 do 7 ugljikovih atoma, cikloalkoksi skupine koja ima 3 do 7 ugljikovih atoma,karboksilne skupine, alkoksikarbonilne skupine koja ima 1 do 6 ugljikovih atoma 1 aciloksi skupine, naftil skupine koja može imati mono- ili dialkilamino skupinu kao supstituent ili tienil skupinu koja za supstituent može imati atom halogena.
the DNA-targeting RNA, or a nucleic acid that encodes the DNA-targeting RNA; and/or 
genetički modificirana stanica domaćin je in vitro ili ex vivo; i/ili
a cylindrical mixing chamber (4) coaxial with and rigidly connected to the drive shaft (2) and having through its peripheral wall a plurality of discharge openings, 
cilindrične komore za miješanje (4) koja je koaksijalna s obzirom na pogonsko vratilo 1 čvrsto je spojena s njim (2) i ima kroz svoju perifernu stijenku mnoštvo otvora za pražnjenje, -
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 4 wherein it is to be administered with a daily dosage of 10 mg. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 4 pri čemu se primjenjuje u dnevnoj dozi od 10 mg.
A triply humanized mouse, comprising a replacement of a genomic DNA of a mouse IL-4Ra gene at an endogenous mouse IL-4Ra locus with a human genomic DNA of a human IL-4Ra gene to form a humanized IL-4Ra gene, wherein the genomic DNA of the mouse IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the mouse IL-4Ra gene, and the human genomic DNA of the human IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the human IL-4Ra gene, wherein the humanized IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the human IL-4Ra gene and exons 6-9 of the mouse IL-4Ra gene, wherein expression of the humanized IL-4Ra gene is under control of the mouse IL-4Ra promoter at the endogenous mouse IL-4Ra locus, 
Glodavac, naznačen time što sadrži zamjenu genomskog fragmenta gena za glodavački IL-4Ra na lokusu za endogeni glodavački IL-4Ra genomskim fragmentom gena za ljudski ILA-Ra kako bi se dobilo gen za humanizirani IL-4Ra koji sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ra, te kodirajuće egzone 6-9 gena za glodavački IL-4Ra, gdje genomski fragment gena za glodavački IL-4Ra sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za glodavački IL-4Ra, a genomski fragment gena za ljudski IL-4Ro sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Roa, te gdje je eksprimiranje gena za humanizirani IL-4Ra pod kontrolom regulacijskih elemenata glodavačkog IL-4Ra. na lokusu za endogeni glodavački IL-4Ra.
Said passages 126 are constituted by through holes 127, which are provided on the upper portion 113a that is folded under the insole 116. 
Navedeni prolazi 126 su izvedeni kroz perforacije 127, koje se nalaze na dijelu gornjišta 113a koje se savija ispod unutarnjeg potplata 116.
In preferred embodiments, the composition comprises at least one antibody that specifically binds to endosialin. 
Rekombinantna stanica koja eksprimira protutijelo koje se specifično veže na endosijalin, naznačena time što navedeno protutijelo proizvode stanice s ATCC pristupnim br.
The method of claim 1, wherein said at least two compounds are formulated with a drug eluting polymer, a bio molecule, a micelle or liposome-forming lipids or oil in water emulsions, or pegylated or solid nanoparticles or microparticles for oral or parenteral or intratechal administration to modify tissue distribution or bioavailability. 
Smjesa ili uporaba prema bilo kojem od zahtjeva 1 do 9, gdje su ta barem dva spoja oblikovana s polimerom za eluaciju lijeka, biomolekulom, micelom ili lipidima koji formiraju liposom ili emulzijom ulje u vodi, ili pegiliranim ili čvrstim nanočesticama ili mikročesticama za oralnu ili pareneteralnu ili intratekalnu primjenu radi modifikacije distribucije tkiva ili bioraspoloživosti.
The modified release pharmaceutical composition of claim 1, for use in inhibiting aldose reductase or affording cardioprotection in a subject in need thereof. 
Farmaceutski oblik s prilagođenim otpuštanjem prema zahtjevu 1, za uporabu u postupku inhibicije aldoza reduktaze kod subjekta kojem je to potrebno; ili za uporabu kardiozaštite kod subjekta kojem je to potrebno.
reacting a compound of formula 2a with an amine of formula 3 to provide a compound of formula 2b 
reakciju spoja sa formulom 2a sa aminom sa formulom 3 da se dobije spoj sa formulom 2b [image]
Preferably, the distance can be adjusted by less than 1 mm, most preferably less than 0.5 mm. 
Uređaj u skladu s patentnim zahtjevom 7, naznačen time što se razmak, odnosno razmaci mogu namještati s točnošću koja je manja od 1 mm.
The method according to claim 1, wherein said compound is not substantially converted into active pregnenolone down stream derivatives after administration to a subject. 
Tvar derivat pregnenolona u skladu s patentnim zahtjevom 1, pri čemu navedena tvar nakon davanja subjektu nije sadržajno dalje pregrađena u aktivne derivate pregnenolona.
R1− represents an anion associated with the positive charge of the N atom. 
R1 predstavlja anion povezan s pozitivnim nabojem na N atomu; i
This goal is solved according to an inventive aspect in such way that the total displacement of the actuation element and/or the volume of the accumulation chamber, preferentially the respective interior height, are previously defined as a function at least of the type of aromatic substance, or of the dimension of the grain of said substance, or of the interior volume of the capsule. 
Kapsula u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da je ukupni pomak elementa za pokretanje (5; 5e, 5s) 1 / ili volumena akumulacijske komore (6), poželjno unutarnja visina, unaprijed definiran kao funkcija najmanje jedne vrste aromatskih tvari ili veličine zrna navedene tvari ili unutarnjeg volumena kapsule (1,
reducing the compound of formula (XX-S); to yield the corresponding compound of formula (X-S). 
(X-5) reduciranje spoja formule (XX-S); kako bi se dobio odgovarajući spoj formule (X-S).
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-B-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to Claim 9, wherein said anti-proliferative agent is carboplatin. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 9, gdje navedeni anti-proliferativni agens je karboplatin.
The reaction mixture is heated under reflux for 5 h. 
Reakcijsku smjesu grije se 5 sati na refluksu.
In another embodiment of this aspect, there is provided an oligonucleotide for use, wherein said oligonucleotide is repetitively administered as a single exposure on three separate occasions 4 weeks apart. 
Oligonukleotid za primjenu prema patentnom zahtjevu 1 ili 2, naznačen time, što se predmetni oligonukleotid opetovano primjenjuje u obliku jednokratne izloženosti u tri različita navrata u razmaku od 4 tjedna.
The pharmaceutical composition of claim 14, wherein the montelukast sodium is present in an amount of about 2% by weight, hydroxypropylcellulose is present in an amount of about 2% by weight, sodium starch glycolate is present in an amount of about 5% by weight, mannitol is present in an amount of about 87% by weight, color iron oxide is present in an amount of about 0.5% by weight, aspartame is present in an amount of about 0.5% by weight, flavoring agent is present in an amount of about 2% by weight, and magnesium stearate is present in an amount of about 1% by weight. 
Farmaceutska kompozicija prema patentnom zahtjevu 13, naznačena time što je montelukast natrij prisutan u količini od oko 5 težinskih %, laktoza monohidrat je prisutna u količini od oko 62 težinska %, hidroksipropilceluloza je prisutna u količini od oko 2 težinska %, škrob je prisutan u količini od oko 18 težinskih %, natrijev škrob glikolat je prisutan u količini od oko 9 težinskih %, magnezijev stearat je prisutan u količini od oko 1 težinski % i sredstvo za oblaganje je prisutno u količini od oko 3 težinska %.
Preferred alkenyl groups have 2 to 12 carbon atoms in the chain; and more preferably about 2 to 4 carbon atoms in the chain. 
Poželjne alkenilne skupine imaju 2 do 12 ugljikovih atoma u lancu; poželjnije otprilike 2 do 4 ugljikova atoma u lancu.
Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxyl toluene, butylated hydroxyanisole and ethylenediamine tetraacetic acid may be added at levels safe for ingestion to improve storage stability. 
Konzervansi 1 kelatirajuća sredstva, kao što su alkohol, natrijev benzoat, butilirani hidroksil toluen, butilirani hidroksianisol 1 etilendiamino tetraoctena kiselina, mogu se dodati u količinama koje su sigurne za probavu, a radi poboljšanja stabilnosti pri čuvanju.
A pharmaceutical composition comprising a therapeutically effective amount of a compound with the formula: a stabilizing amount of one or more antioxidants selected from the group consisting of butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, ascorbyl palmitate, propyl gallate, dodecyl gallate, ethyl gallate, octyl gallate, alpha tocopherol, sodium ascorbate, sodium metabisulfite, fumaric acid, and malic acid, and optionally one or more pharmaceutical acceptable excipients selected from the group consisting of microcrystalline cellulose, starch, hydroxypropylcellulose, sodium starch glycolate, isopropyl alcohol, magnesium stearate, and combinations thereof. 
HR P20151438 T1 HR P20151438 T1 PATENTNI ZAHTJEVI stabilizirajuću količinu jednog ili više antioksidanasa odabranih iz grupe koja se sastoji od butiliranog hidroksianisola, butiliranog hidroksitoluena, askorbinske kiseline, askorbil palmitata, propil galata, dodecil galata, etil galata, oktil galata, alfa tokoferola, natrijevog askorbata, natrijevog metabisulfita, fumarinske kiseline i maleinske kiseline, i opcionalno jednog ili više farmaceutski prihvatljivih ekscipijenasa odabranih iz grupe koja se sastoji od mikrokristalinične celuloze, škroba, hidroksipropilceluloze, natrijevog škrobnog glikolata, izopropilnog alkohola, magnezijevog stearata i njihovih kombinacija.
The system of claim 7, wherein the system is configured to combine the pulses (601 a, 601b) provided by the first pump segment (103a) and the second pump segment (103b) to form a resultant flow that has pulsation amplitudes that are smaller than pulsation amplitudes of the pulses provided by the first pump segment and smaller than pulsation amplitudes of the pulses provided by the second pump segment. 
Sustav prema zahtjevu 7, naznačen time, da je sustav uređen tako da kombinira pulseve (601a, 601b) dobivene od prvog segmenta (1034) sisaljke 1 drugog segmenta (103b) sisaljke za tvorbu rezultante protoka, čije su pulsacijske amplitude manje nego pulsacijske amplitude pulseva dobivenih od prvog segmenta sisaljke i manje nego pulsacijske amplitude pulseva dobivenih od drugog segmenta sisaljke.
Method according to claim 9 wherein said leaves are obtained from plants of the family Theaceae, preferably the order of Camellia and more preferably selected from the group comprising C . sinensis, C. taliensis and C . irrawadiensis. 
Postupak prema zahtjevu 9, naznačen time, da je spomenuto lišće dobiveno iz biljne porodice Theaceae, poželjno iz reda Camellia, a posebno odabrano iz skupine koja sadrži C. sinensis, C. taliensis 1 C. irrawadiensis.